



PTO/SB/21 (08-06)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1645
#51
TECH CENTER 1600/290RECEIVED
DEC 1 9 2002

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/073,402
Filing Date	February 11, 2002
First Named Inventor	Steinbeck et al.
Group Art Unit	1645
Examiner Name	To be assigned
Attorney Docket Number	003252-053321

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449; References CA through CCJ; Certificate of Mailing; Return Receipt Postcard.
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

The Commissioner is authorized to charge fee deficiencies to the NIXON PEABODY LLP deposit account 50-0850.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David S. Resnick (Reg. No. 34,235) NIXON PEABODY LLP, 101 Federal Street, Boston, MA 02110
Signature	
Date	12/15/02

CERTIFICATE OF MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 12/15/02

Typed or printed name	Melissa Kruggel
Signature	
Date	12/15/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on 12/15/02
.Date

Melissa Kruggel
Signature

Melissa Kruggel

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Form (PTO/SB/21)(1 pg);
Information Disclosure Statement with attached Form PTO-1449 (5 pp);
References marked CA through CCJ;
Certificate of Mailing (1 pg.); and
Return Receipt Postcard.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Docket No. 003252-053321

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Steinbeck et al.

Serial No.: 10/073,402

Group: 1645

Filed: February 11, 2002

Examiner: To be assigned

For: DIAGNOSTIC FOR INFLAMMATORY DISEASES ASSOCIATED WITH
CARTILAGE AND BONE SURFACES

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 12/15/02

Melissa Kruggel

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

— (2) within three months of the mailing date of the PCT International Search Report; or

— (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or

— (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

X are enclosed herewith; and
— have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850 or 14-1138. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



David S. Resnick (Reg. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057

Date: 12/5/02



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			DOCKET NO.: 053321		SERIAL NO.: 10/073,402		
			APPLICANT(S): Steinbeck et al.				
			FILING DATE: 2/11/02		GROUP NO.: 1645		
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	INVENTOR/ASSIGNEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
							RECEIVED
							DEC 10 2002
							TECH CENTER 1600/2900
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	CA	Babior, B.M., <i>Blood</i> 64(5), 959-66, 1984					
	CB	Babior, B.M., et al., <i>J. Clin. Invest.</i> 52(3), 741-4, 1973					
	CC	Bainton, D.F., Farquhar, M.G., <i>J. Cell Biol.</i> 39(2), 299-317, 1968					
	CD	Briggs, R.T., et al., <i>J. Cell Biol.</i> 67(3), 566-86, 1975					
	CE	Davies, J.M., et al., <i>Free Radic. Biol. Med.</i> 15(6), 637-43, 1993					
	CF	Eyre, D.R., <i>Science</i> 207, 1315-1322, 1980					


O 15
DEC 09 2002PAP
TRADEMA

FORM PTO-1462 TRADEMA		DOCKET NO.: 053321	SERIAL NO.: 10/073,402
INFORMATION DISCLOSURE		APPLICANT(S): Steinbeck et al.	
STATEMENT		FILING DATE: 2/11/02	GROUP NO.: 1645
	CG	Fredriksson, M.I., et al., <i>J. Periodontal</i> 70(11), 1355-1360, 1999	
	CH	Fredriksson, M., et al., <i>J. Clin. Periodontol</i> 25(5), 394-8, 1998	
	CI	Fujimoto, D., et al., <i>Biochem. Biophys. Res. Commun</i> 84(1), 52-7, 1978	
	CJ	Gartner, A., Weser, U., <i>Top. Curr. Chem.</i> 132, 1-61 (1986)	
	CK	Ginis, I., Tauber, A.I., <i>Blood</i> 76(6), 1233-9, 1990	
	CL	Greenwald, R.A., Moak, S.A. <i>Inflammation</i> 10(1), 15-30, 1986	
	CM	Greenwald, R.A., <i>Semin. Arthritis Rheum.</i> 20(4), 219-40, 1991	
	CN	Halliwell, B., <i>Ann. Rheum. Dis.</i> 54(6), 505-10, 1995	
	CO	Harlan, J.M., <i>Blood</i> 65(3), 513-25 1985	
	CP	Harris, E.D. Jr., <i>Inflammation: Basic Principles and Clinical Correlates</i> (Gallin, J.I., Goldstein, I.M., Snyderman, R., ed), 751-773, Raven Press, Ltd., New York, 1988	
	CQ	Harrison, J.E., Schultz, J., <i>J. Biol. Chem.</i> 251(5), 1371-4, 1976	
	CR	Hazen, S.L., et al., <i>J. Clin. Invest.</i> 98(6), 1283-9, 1996	
	CS	Henson, P.M., Johnston, R.B., Jr., <i>J. Clin. Invest.</i> 79(3), 669-74, 1987	
	CT	Hurst, J.K., Barrette, W.C., Jr., <i>Crit. Rev. Biochem. Mol. Biol.</i> 24(4), 271-328, 1989	
	CU	Klebanoff, S.J., <i>Inflammation: Basic Principles and Clinical Correlates</i> (Gallin, J.I., Goldstein, I.M., Snyderman, R., ed), 391-444, Raven Press, Ltd., New York, 1988	
	CV	McCord, J.M., and Fridovich, I., <i>J. Biol. Chem.</i> 243(21), 5753-60 (1968)	

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			DOCKET NO.: 053321	SERIAL NO.: 10/073,402
			APPLICANT(S): Steinbeck et al.	
			FILING DATE: 2/11/02	GROUP NO.: 1645
	CW	Rossi, F., <i>Biochimica et Biophysica Acta</i> 853, 65-89, 1986		
	CX	Segal, A.W., et al., <i>Lancet</i> 2 (8087), 446-9, 1978		
	CY	Selvaraj, R.J., et al., <i>J. Infect. Dis.</i> 137(4), 481-5, 1978		
	CZ	Steinbeck, M.J., et al., <i>J. Biol. Chem.</i> 267(19), 13425-33, 1992		
	CCA	Thomas, E.L., et al., <i>Methods Enzymol.</i> 132, 569-85, 1986		
	CCB	Vissers, M.C., et al., <i>Blood</i> 66(1), 161-6, 1985		
	CCC	Vissers, M.C., Winterbourn, C.C., <i>Arch. Biochem. Biophys.</i> 285(1), 53-9, 1991		
	CCD	Vissers, M.C., Winterbourn, C.C., <i>Arch. Biochem. Biophys.</i> 285(2), 357-64, 1991		
	CCE	Vissers, M.C., Winterbourn, C.C., <i>Biochem. Biophys. Acta</i> 889(3), 277-86, 1986		
	CCF	Weiss, S.J., et al., <i>J. Clin. Invest.</i> 70(3), 598-607, 1982		
	CCG	Weiss, S.J., et al., <i>Science</i> 222 (4624), 625-628, 1983		
	CCH	Weiss, S.J., LoBuglio, A.F., <i>Lab. Invest.</i> 47(1), 5-18, 1982		
	CCI	Woolley, D.E., et al., <i>Ann. Rheum. Dis.</i> 56(3), 151-61, 1997		
	CCJ	Eyre, D.R., <i>The Chem. and Bio. of Mineralized Connective Tissues</i> (Veis, A., ed), 51-55, Elsevier North Holland, Inc., 1981		

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900